Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LA-EP2006 · 2 trials · 5 indications
Mean duration of severe neutropenia, defined as number of consecutive days with ANC \<0.5 × 10\^9 cells/L (grade 4 neutropenia).
| Arm | Type | Description |
|---|---|---|
| Neulasta® | ACTIVE_COMPARATOR | During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application. |
| LA-EP2006 | EXPERIMENTAL | During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application. |
| Name | Type | Description |
|---|---|---|
| LA-EP2006 | DRUG | Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application. |
| Neulasta® | DRUG | Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application. |
Inclusion Criteria: * histologically proven breast cancer * eligible for six cycles of neoadjuvant or adjuvant chemotherapy Exclusion Criteria: * concurrent or prior chemotherapy for breast cancer * concurrent or prior anti-cancer treatment for breast cancer such as endocrine therapy, immunothera...
LA-EP2006 is an investigational small molecule being developed for chemotherapy-induced neutropenia and neutropenic complications in oncology. It is studied in patients receiving chemotherapy, particularly those with breast cancer, to compare its efficacy and safety against peg-filgrastim.
LA-EP2006 is being developed by Novartis AG, which trades under the ticker NVS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating chemotherapy-induced neutropenia.
LA-EP2006 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed to assess its efficacy and safety compared to peg-filgrastim.
LA-EP2006 has been studied in two completed Phase 3 trials: NCT01516736 and NCT01735175. Both trials compared LA-EP2006 with peg-filgrastim in female patients with breast cancer undergoing chemotherapy, with enrollment of 308 and 316 participants respectively.
LA-EP2006 is a small molecule designed to address chemotherapy-induced neutropenia. Its specific molecular target is not disclosed in available information, but it is being compared to peg-filgrastim, a granulocyte colony-stimulating factor, in clinical trials.
LA-EP2006 is not the same as peg-filgrastim. It is being studied as a potential alternative to peg-filgrastim in Phase 3 trials. The trials are designed to compare the efficacy and safety of LA-EP2006 against peg-filgrastim in treating chemotherapy-induced neutropenia.